Why didn’t we negatively rank Pfizer $PFE US on the recent CEO Share sale?
Albert Bourla’s sale of $5.5m of stock on the announcement of Pfizer’s Covid-19 vaccine success generated significant headlines as it represented 62% of his equity holding. When ranking stocks a key point we look at is the sale relative to their total holding. In the US executives typically have options that are exercisable to become […]